These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1096 related articles for article (PubMed ID: 30877495)
21. Role of diagnostic laparoscopy in patients with suspicion of colorectal peritoneal metastases to evaluate suitability for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Hentzen JEKR; van der Plas WY; Constansia RDN; Been LB; Hoogwater FJH; van Ginkel RJ; van Dam GM; Hemmer PHJ; Kruijff S BJS Open; 2019 Dec; 3(6):812-821. PubMed ID: 31832588 [TBL] [Abstract][Full Text] [Related]
22. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases. Ljunggren M; Nordenvall C; Palmer G Eur J Surg Oncol; 2021 Nov; 47(11):2865-2872. PubMed ID: 34116900 [TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812 [TBL] [Abstract][Full Text] [Related]
24. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884 [TBL] [Abstract][Full Text] [Related]
25. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ihemelandu C; Bijelic L; Sugarbaker PH Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250 [TBL] [Abstract][Full Text] [Related]
26. Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Kotha NV; Baumgartner JM; Veerapong J; Cloyd JM; Ahmed A; Grotz TE; Leiting JL; Fournier K; Lee AJ; Dineen SP; Dessureault S; Clarke C; Mogal H; Zaidi MY; Russell MC; Patel SH; Sussman JJ; Dhar V; Lambert LA; Hendrix RJ; Abbott DE; Pokrzywa C; Lafaro K; Lee B; Greer JB; Fackche N; Lowy AM; Kelly KJ Ann Surg Oncol; 2019 Jul; 26(7):2234-2240. PubMed ID: 31016486 [TBL] [Abstract][Full Text] [Related]
27. Strategies for Managing Intraoperative Discovery of Limited Colorectal Peritoneal Metastases. Mariani A; Gelli M; Sourrouille I; Benhaim L; Faron M; Honoré C; Elias D; Goéré D Ann Surg Oncol; 2019 May; 26(5):1437-1444. PubMed ID: 30805806 [TBL] [Abstract][Full Text] [Related]
28. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients. Mercier F; Passot G; Villeneuve L; Levine EA; Yonemura Y; Goéré D; Sugarbaker PH; Marolho C; Bartlett DL; Glehen O; Ann Surg Oncol; 2018 Apr; 25(4):1094-1100. PubMed ID: 29238881 [TBL] [Abstract][Full Text] [Related]
29. Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer? Cigdem Arslan N; Bisgin T; Altay C; Yavuzsen T; Karaoglu A; Canda AE; Sarioglu S; Sokmen S J BUON; 2018 Dec; 23(7):77-83. PubMed ID: 30722115 [TBL] [Abstract][Full Text] [Related]
31. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience. Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164 [TBL] [Abstract][Full Text] [Related]
32. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [TBL] [Abstract][Full Text] [Related]
33. Comparison of EPIC Versus HIPEC in the Treatment of Colorectal Peritoneal Metastases and Appendix Tumors Using Inverse Probability of Treatment Weighting. Jeong MH; Kang SJ; Park SY; Kwak SG; Seo AN; Park S; Park JS; Kim HJ; Choi GS Ann Surg Oncol; 2024 Oct; 31(10):7111-7121. PubMed ID: 39073661 [TBL] [Abstract][Full Text] [Related]
34. The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases. van der Werf LR; Wassenaar E; de Niet A; Lalezari F; Braam HJ; van Ramshorst B; Nederend J; de Hingh IHJT; Kok NFM; Aalbers AGJ Eur J Surg Oncol; 2019 Mar; 45(3):376-382. PubMed ID: 30414704 [TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy. Zhou S; Jiang Y; Liang J; Pei W; Zhou Z World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125 [TBL] [Abstract][Full Text] [Related]
36. A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. Lee RM; Gamboa AC; Turgeon MK; Zaidi MY; Kimbrough C; Leiting J; Grotz T; Lee AJ; Fournier K; Powers B; Dineen S; Baumgartner JM; Veerapong J; Mogal H; Clarke C; Wilson G; Patel S; Hendrix R; Lambert L; Pokrzywa C; Abbott DE; LaRocca CJ; Raoof M; Greer J; Johnston FM; Staley CA; Cloyd JM; Maithel SK; Russell MC J Surg Oncol; 2021 Jan; 123(1):187-195. PubMed ID: 33002202 [TBL] [Abstract][Full Text] [Related]
37. P.R.O.P.S. - A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Yong ZZ; Tan GHC; Shannon N; Chia C; Teo MCC World J Surg Oncol; 2019 Aug; 17(1):138. PubMed ID: 31391066 [TBL] [Abstract][Full Text] [Related]
38. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients. Piso P; Nedelcut SD; Rau B; Königsrainer A; Glockzin G; Ströhlein MA; Hörbelt R; Pelz J Ann Surg Oncol; 2019 Jan; 26(1):148-154. PubMed ID: 30456672 [TBL] [Abstract][Full Text] [Related]
39. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients. Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213 [TBL] [Abstract][Full Text] [Related]
40. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience. Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]